Opinion|Videos|June 5, 2024
SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, discusses how the SunRISe-1 trial design addresses the need for bladder-sparing treatment options for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC) who are ineligible for or refuse radical cystectomy. He also contrasts the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for muscle-invasive bladder cancer (MIBC), discussing how this chemoimmunotherapy combination may potentially expand treatment options for this patient population.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How does the SunRISe-1 trial design address the need for bladder-sparing treatment options for patients with BCG-unresponsive HR NMIBC who are ineligible or refuse radical cystectomy? Discuss the rationale for investigating the combination of TAR-200 and cetrelimab, as well as the TAR-200 and cetrelimab monotherapy approaches, in this patient population and how the preliminary results from the combination cohort compare to the monotherapy cohorts.
- Contrast the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for MIBC. How might this chemoimmunotherapy combination potentially expand treatment options for this patient population?
Advertisement
Related to this article
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Advertisement
Advertisement
Trending on AJMC
1
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5